市場調查報告書
商品編碼
1417393
全球內視鏡逆行性造影(ERCP) 市場:趨勢、預測與競爭分析(~2030 年)Endoscopic Retrograde Cholangiopancreatography Market Report: Trends, Forecast and Competitive Analysis to 2030 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
內視鏡逆行性造影的趨勢與預測
至2030年,全球內視鏡逆行性造影市場規模預計將達19億美元,2024年至2030年年複合成長率為5.5%。該市場的主要驅動力是癌症發病率上升、對微創手術/手術的日益偏好以及政府和醫療機構不斷增加的財務承諾。全球內視鏡逆行性造影市場的未來充滿希望,醫院和門診手術中心/診所市場充滿機會。
內視鏡逆行性造影市場洞察
Lucintel 預測,由於胃腸道疾病的盛行率不斷增加,內視鏡治療設備在預測期內仍將是最大的細分市場。
在這個市場中,醫院可能仍然是最大的細分市場,因為這些設施中提供了廣泛的 ERCP 設備。
由於癌症患者數量的增加和先進 ERCP 工具的引入,在預測期內,北美可能仍然是最大的地區。
Q1.市場規模有多大?
A1. 到 2030 年,全球內視鏡逆行性造影市場預計將達到 19 億美元。
Q2.市場成長預測如何?
A2. 2024年至2030年,全球內視鏡逆行性造影市場預計將以5.5%的年複合成長率成長。
Q3.影響市場成長的主要促進因素有哪些?
A3. 該市場的主要驅動力是癌症發病率上升、對微創手術和手術的日益偏好以及政府和醫療機構不斷增加的財政承諾。
Q4.市場的主要細分市場是什麼?
A4. 內視鏡逆行性造影市場的未來前景廣闊,醫院和門診手術中心/診所市場充滿機會。
Q5.市場上主要企業有哪些?
A5. 進行內視鏡逆行性造影的主要企業如下。
Q6.未來最大的細分市場是什麼?
A6.Lucintel 預計,由於胃腸道疾病的盛行率不斷增加,內視鏡治療設備在預測期內仍將是其最大的細分市場。
Q7. 未來五年預計哪個地區將成為最大的市場?
A7. 由於癌症患者的增加和先進的 ERCP 工具的引入,在預測期內,北美將繼續成為最大的地區。
Q8. 可以客製化報告嗎?
A8. 是的,Lucintel 提供 10% 的客製化服務,無需額外付費。
Endoscopic Retrograde Cholangiopancreatography Trends and Forecast
The future of the global endoscopic retrograde cholangiopancreatography market looks promising with opportunities in the hospital and ambulatory surgery center & clinic markets. The global endoscopic retrograde cholangiopancreatography market is expected to reach an estimated $1.9 billion by 2030 with a CAGR of 5.5% from 2024 to 2030. The major drivers for this market are elevated cancer rates, increasing inclination towards minimally invasive procedures and surgeries, and growing financial commitments from governments and healthcare institutions.
A more than 150-page report is developed to help in your business decisions.
Endoscopic Retrograde Cholangiopancreatography by Segment
The study includes a forecast for the global endoscopic retrograde cholangiopancreatography by product, procedure, end use, and region.
List of Endoscopic Retrograde Cholangiopancreatography Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies endoscopic retrograde cholangiopancreatography companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the endoscopic retrograde cholangiopancreatography companies profiled in this report include-
Endoscopic Retrograde Cholangiopancreatography Market Insights
Lucintel forecasts that endotherapy device will remain the largest segment over the forecast period due to growing incidence of gastrointestinal disorders.
Within this market, hospital will remain the largest segment due to availability of wide range of ERCP devices in these facilities.
North America will remain the largest region over the forecast period due to rising frequency of cancer cases and introduction of advanced ERCP tools in the region.
Features of the Global Endoscopic Retrograde Cholangiopancreatography Market
Market Size Estimates: Endoscopic retrograde cholangiopancreatography market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.
Segmentation Analysis: Endoscopic retrograde cholangiopancreatography market size by product, procedure, end use, and region in terms of value ($B).
Regional Analysis: Endoscopic retrograde cholangiopancreatography market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different products, procedures, end uses, and regions for the endoscopic retrograde cholangiopancreatography market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the endoscopic retrograde cholangiopancreatography market.
Analysis of competitive intensity of the industry based on Porter's Five Forces model.
FAQ
Q1. What is the endoscopic retrograde cholangiopancreatography market size?
Answer: The global endoscopic retrograde cholangiopancreatography market is expected to reach an estimated $1.9 billion by 2030.
Q2. What is the growth forecast for endoscopic retrograde cholangiopancreatography market?
Answer: The global endoscopic retrograde cholangiopancreatography market is expected to grow with a CAGR of 5.5% from 2024 to 2030.
Q3. What are the major drivers influencing the growth of the endoscopic retrograde cholangiopancreatography market?
Answer: The major drivers for this market are elevated cancer rates, increasing inclination towards minimally invasive procedures and surgeries, and growing financial commitments from governments and healthcare institutions.
Q4. What are the major segments for endoscopic retrograde cholangiopancreatography market?
Answer: The future of the endoscopic retrograde cholangiopancreatography market looks promising with opportunities in the hospital and ambulatory surgery center & clinic markets.
Q5. Who are the key endoscopic retrograde cholangiopancreatography market companies?
Answer: Some of the key endoscopic retrograde cholangiopancreatography companies are as follows.
Q6. Which endoscopic retrograde cholangiopancreatography market segment will be the largest in future?
Answer: Lucintel forecasts that endotherapy device will remain the largest segment over the forecast period due to growing incidence of gastrointestinal disorders.
Q7. In endoscopic retrograde cholangiopancreatography market, which region is expected to be the largest in next 5 years?
Answer: North America will remain the largest region over the forecast period due to rising frequency of cancer cases and introduction of advanced ERCP tools in the region.
Q.8 Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.